IL158329A0 - Antiangiogenic combination therapy for the treatment of cancer - Google Patents

Antiangiogenic combination therapy for the treatment of cancer

Info

Publication number
IL158329A0
IL158329A0 IL15832902A IL15832902A IL158329A0 IL 158329 A0 IL158329 A0 IL 158329A0 IL 15832902 A IL15832902 A IL 15832902A IL 15832902 A IL15832902 A IL 15832902A IL 158329 A0 IL158329 A0 IL 158329A0
Authority
IL
Israel
Prior art keywords
cancer
treatment
combination therapy
antiangiogenic
antiangiogenic combination
Prior art date
Application number
IL15832902A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of IL158329A0 publication Critical patent/IL158329A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15832902A 2001-04-25 2002-04-25 Antiangiogenic combination therapy for the treatment of cancer IL158329A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/843,132 US20020103141A1 (en) 1998-12-23 2001-04-25 Antiangiogenic combination therapy for the treatment of cancer
PCT/US2002/013219 WO2002085459A2 (en) 2001-04-25 2002-04-25 Antiangiogenic combination therapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL158329A0 true IL158329A0 (en) 2004-05-12

Family

ID=25289143

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15832902A IL158329A0 (en) 2001-04-25 2002-04-25 Antiangiogenic combination therapy for the treatment of cancer

Country Status (15)

Country Link
US (2) US20020103141A1 (ja)
EP (1) EP1414526A2 (ja)
JP (1) JP2004529150A (ja)
KR (1) KR20040018364A (ja)
CN (1) CN1520324A (ja)
BR (1) BR0209269A (ja)
CA (1) CA2444219A1 (ja)
CZ (1) CZ20032783A3 (ja)
EA (1) EA200301104A1 (ja)
IL (1) IL158329A0 (ja)
MX (1) MXPA03009886A (ja)
NO (1) NO20034780L (ja)
PL (1) PL367198A1 (ja)
WO (1) WO2002085459A2 (ja)
ZA (1) ZA200402546B (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
DE50104561D1 (de) * 2001-12-04 2004-12-23 Brahms Ag Verfahren zur Diagnose von Sepsis unter Bestimmung löslicher Cytokeratinfragmente
GB0208516D0 (en) * 2002-04-15 2002-05-22 Univ Liverpool Chemotherapy
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
CN1720044A (zh) * 2002-11-06 2006-01-11 惠氏公司 急性白血病和骨髓异常增生综合征的组合治疗
US7332525B2 (en) 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20050187172A1 (en) * 2003-12-23 2005-08-25 Masferrer Jaime L. Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia
JP2008507502A (ja) * 2004-07-23 2008-03-13 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換２−トリフルオロメチル−２ｈ−クロメン−３−カルボン酸誘導体を分離するためのエナンチオ選択的方法
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
PT1827437E (pt) * 2004-12-15 2012-01-12 Sigma Tau Ind Farmaceuti Combinação de agentes terapêuticos para o tratamento do cancro
PT2056805E (pt) * 2006-08-16 2011-09-02 Action Medicines Sl Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
KR20100127210A (ko) 2008-01-23 2010-12-03 헤를레브 하스피틀 비특이적 질환용 일반 마커로서의 ｙｋｌ-40
EP2338486A1 (en) 2009-12-18 2011-06-29 Johannes Gutenberg-Universität Mainz 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
GB201000196D0 (en) * 2010-01-07 2010-02-24 Galvez Julian M Novel combination
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
AU2013352223B2 (en) * 2012-11-28 2019-07-18 Nektar Therapeutics Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor
CN103012350B (zh) * 2012-12-07 2015-02-04 中国科学院广州生物医药与健康研究院 苯并吡喃类手性化合物的合成方法
TWI646091B (zh) 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
KR20200026893A (ko) 2017-06-12 2020-03-11 스탠니슬로우 알 벌진스키 연수막 질환의 치료 방법
PE20210641A1 (es) 2018-03-08 2021-03-23 Incyte Corp COMPUESTOS DIOLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ506515A (en) * 1996-10-15 2002-05-31 G COX-2 inhibitor (4-[5-(4-chlorophenyl)-3(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide) for treating neoplasia
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
PT952148E (pt) * 1998-04-10 2004-09-30 Pfizer Prod Inc Derivados de acido ciclobutil-ariloxiarilsulfonilamino-hidroxamico
PA8469401A1 (es) * 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) * 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
US6294558B1 (en) * 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6277878B1 (en) * 1998-09-07 2001-08-21 Pfizer Inc Substituted indole compounds as anti-inflammatory and analgesic agents
ES2213985T3 (es) * 1998-11-05 2004-09-01 Pfizer Products Inc. Derivados de hidroxiamida de acido 5-oxo-pirrolidin-2-carboxilico.
BR9916518A (pt) * 1998-12-23 2002-01-29 Searle & Co Método para tratar ou prevenir um distúrbio de neoplasia em um mamìfero em necessidade de tal tratamento ou prevenção, e, combinação compreendendo um inibidor de ciclooxigenase-2 e um ou mais agentes anti-neoplásticos
EP1041072B1 (en) * 1999-03-31 2003-07-16 Pfizer Products Inc. Dioxocyclopentyl hydroxamic acids
MXPA00006605A (es) * 1999-07-02 2004-12-09 Pfizer Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.

Also Published As

Publication number Publication date
CN1520324A (zh) 2004-08-11
WO2002085459A3 (en) 2004-03-04
CA2444219A1 (en) 2002-10-31
EP1414526A2 (en) 2004-05-06
WO2002085459A2 (en) 2002-10-31
MXPA03009886A (es) 2004-11-22
KR20040018364A (ko) 2004-03-03
ZA200402546B (en) 2005-04-26
NO20034780L (no) 2003-12-12
BR0209269A (pt) 2004-06-22
PL367198A1 (en) 2005-02-21
US20040127539A1 (en) 2004-07-01
NO20034780D0 (no) 2003-10-24
EA200301104A1 (ru) 2004-06-24
US20020103141A1 (en) 2002-08-01
CZ20032783A3 (cs) 2004-11-10
JP2004529150A (ja) 2004-09-24

Similar Documents

Publication Publication Date Title
IL158329A0 (en) Antiangiogenic combination therapy for the treatment of cancer
IL164599A0 (en) Combination therapy for the treatment of cancer
IL251270A0 (en) Cancer treatment
HUP0500424A2 (en) Combination therapy for the treatment of cancer
EP1446012A4 (en) Bacteriolytic combination therapy for the treatment of tumors
EP1311262A4 (en) COMBINED TREATMENT AGAINST CANCER
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
EP1534074A4 (en) POLYTHERAPY FOR THE TREATMENT OF OBESITY
HUP0400024A2 (hu) Neoplasztikus betegségek kezelésére szolgáló gyógyszerkombinációk
EP1442062A4 (en) METHOD FOR TREATING CARCINOMA
IL136960A0 (en) Combination therapy for the treatment of migraine
AU2003251875A8 (en) Combination therapy for the treatment of neoplasms
GB2389532C (en) The method of treating cancer
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
PL368035A1 (en) Compositions and methods for the treatment of cancer
EP1401494A4 (en) TUMOR THERAPY
AU2001285156A1 (en) Combination therapy for the treatment of migraine
IL136025A0 (en) Combination therapy for the treatment of migraine
IL136962A0 (en) Combination therapy for the treatment of migraine
IL149281A0 (en) Treatment of cancer
IL136024A0 (en) Combination therapy for the treatment of migraine
EP1463511A4 (en) COMBINATORY ANTICANCER THERAPY
GB2397018B (en) Combination therapy for treating disease